TABLE 2.
Tumor fates in female Pirc/+ rats fed diets supplemented with 25(OH)D3 or vitamin D31
Tumor fate, % |
|||||
Dietary compound and dose2 | Total colonic tumors followed, n | Grew | Remained static | Regressed | P-value |
25(OH)D3 [μg/(kg body weight · d)] | |||||
0 | 40 | 75 | 20 | 5 | |
60 | 28 | 64 | 36 | 0 | 0.10 |
170 | 25 | 96 | 0 | 4 | <0.0001 |
500 | 24 | 83 | 13 | 4 | 0.15 |
1500 | 37 | 78 | 19 | 3 | 0.57 |
3000 | 28 | 71 | 29 | 0 | <0.0013 |
4500 | 67 | 76 | 21 | 3 | 0.86 |
Vitamin D3 [μg/(kg body weight · d)] | |||||
0 | 22 | 91 | 9 | 0 | |
6 | 14 | 93 | 7 | 0 | 0.60 |
60 | 30 | 73 | 27 | 0 | 0.001 |
500 | 31 | 94 | 6 | 0 | 0.49 |
1500 | 11 | 100 | 0 | 0 | 0.002 |
25(OH)D3, 25-hydroxycholecalciferol.
Dose = the supplementation of base diet, which contains 1 IU vitamin D3/g diet.
Dose-treated compared with contemporaneous vehicle-treated rats from the vitamin D3 study.